XtenCHO ™ Race Cells

XtenCHO Race: Accelerating Transient Gene Expression for High-Yield Protein Production

XtenCHO Race cells are an advanced Chinese Hamster Ovary (CHO) cell line, specifically derived from CHO-K1, designed to optimize transient gene expression. This innovative cell line enables researchers to achieve exceptionally high protein yields in just 8 days of culture, significantly reducing production timelines while maintaining robust expression levels.
Why Choose CHO Cells for Transient Gene Expression?

CHO cell lines have long been the gold standard in biopharmaceutical research, particularly for therapeutic protein production. Their unique advantages include:

– Mammalian Protein Processing: CHO cells offer human-like post-translational modifications, essential for ensuring the correct folding, glycosylation, and bioactivity of recombinant proteins.
– High Transfection Efficiency: CHO cells, particularly those optimized for transient expression, support high plasmid uptake, maximizing protein output.
– Scalability: Whether in small-scale lab experiments or large-scale bioprocesses, CHO cells can be adapted to various culture formats, including suspension and bioreactor systems.
– Regulatory Compliance: CHO-derived proteins are widely accepted by regulatory agencies, making them the preferred choice for preclinical and therapeutic research.

Why Use XtenCHO Race Cells?

XtenCHO Race is specifically engineered for rapid, high-yield protein production, offering researchers several key benefits:

-Unmatched Speed: Achieve high titers in just 8 days, accelerating experimental workflows and reducing time-to-data.
-Optimized Productivity: Designed for superior transient transfection efficiency, XtenCHO Race outperforms conventional CHO-K1 cells in yield.
-Seamless Integration: Optimised with XtenCHO Race reagents, all included in XtenCHO Race Starter kit, allowing for easy adoption into existing protocols.

By leveraging XtenCHO Race cells, researchers can streamline protein expression workflows, enhance reproducibility, and accelerate the development of biologics, including monoclonal antibodies and recombinant therapeutics.